Wall Brian F, Magee Kirk, Campbell Samuel G, Zed Peter J
Department of Emergency Medicine, North York General Hospital, 4001 Leslie St, Toronto, Ontario, Canada, M2K 1E1.
Department of Emergency Medicine, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8.
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD010698. doi: 10.1002/14651858.CD010698.pub2.
Procedural sedation and analgesia (PSA) is used frequently in the emergency department (ED) to facilitate painful procedures and interventions. Capnography, a monitoring modality widely used in operating room and endoscopy suite settings, is being used more frequently in the ED setting with the goal of reducing cardiopulmonary adverse events. As opposed to settings outside the ED, there is currently no consensus on whether the addition of capnography to standard monitoring modalities reduces adverse events in the ED setting.
To assess whether capnography in addition to standard monitoring (pulse oximetry, blood pressure and cardiac monitoring) is more effective than standard monitoring alone to prevent cardiorespiratory adverse events (e.g. oxygen desaturation, hypotension, emesis, and pulmonary aspiration) in ED patients undergoing PSA.
We searched the Cochrane Central Register of Controlled Trials (2016, Issue 8), and MEDLINE, Embase, and CINAHL to 9 August 2016 for randomized controlled trials (RCTs) and quasi-randomized trials of ED patients requiring PSA with no language restrictions. We searched meta-registries (www.controlled-trials.com, www.clinicalstudyresults.org, and clinicaltrials.gov) for ongoing trials (February 2016). We contacted the primary authors of included studies as well as scientific advisors of capnography device manufacturers to identify unpublished studies (February 2016). We handsearched conference abstracts of four organizations from 2010 to 2015.
We included any RCT or quasi-randomized trial comparing capnography and standard monitoring to standard monitoring alone for ED patients requiring PSA.
Two authors independently performed study selection, data extraction, and assessment of methodological quality for the 'Risk of bias' tables. An independent researcher extracted data for any included studies that our authors were involved in. We contacted authors of included studies for incomplete data when applicable. We used Review Manager 5 to combine data and calculate risk ratios (RR) and 95% confidence intervals (CI) using both random-effects and fixed-effect models.
We identified three trials (κ = 1.00) involving 1272 participants. Comparing the capnography group to the standard monitoring group, there were no differences in the rates of oxygen desaturation (RR 0.89, 95% CI 0.48 to 1.63; n = 1272, 3 trials; moderate quality evidence) and hypotension (RR 2.36, 95% CI 0.98 to 5.69; n = 986, 1 trial; moderate quality evidence). There was only one episode of emesis recorded without significant difference between the groups (RR 3.10, 95% CI 0.13 to 75.88, n = 986, 1 trial; moderate quality evidence). The quality of evidence for the primary outcomes was moderate with downgrades primarily due to heterogeneity and reporting bias.There were no differences in the rate of airway interventions performed (RR 1.26, 95% CI 0.94 to 1.69; n = 1272, 3 trials; moderate quality evidence). In the subgroup analysis, we found a higher rate of airway interventions for adults in the capnography group (RR 1.44, 95% CI 1.16 to 1.79; n = 1118, 2 trials; moderate quality evidence) with a number needed to treat for an additional harmful outcome of 12. Although statistical heterogeneity was reduced, there was moderate quality of evidence due to outcome definition heterogeneity and limited reporting bias. None of the studies reported recovery time.
AUTHORS' CONCLUSIONS: There is a lack of convincing evidence that the addition of capnography to standard monitoring in ED PSA reduces the rate of clinically significant adverse events. Evidence was deemed to be of moderate quality due to population and outcome definition heterogeneity and limited reporting bias. Our review was limited by the small number of clinical trials in this setting.
在急诊科(ED),程序性镇静镇痛(PSA)常用于辅助进行疼痛性操作和干预。二氧化碳描记法作为一种在手术室和内镜检查室广泛使用的监测方式,目前在急诊科也越来越频繁地被使用,目的是减少心肺不良事件。与急诊科以外的环境不同,目前对于在急诊科环境中,在标准监测方式基础上增加二氧化碳描记法是否能减少不良事件尚无共识。
评估在接受PSA的急诊科患者中,除标准监测(脉搏血氧饱和度、血压和心脏监测)外,增加二氧化碳描记法是否比单纯标准监测更有效地预防心肺不良事件(如氧饱和度降低、低血压、呕吐和肺误吸)。
我们检索了Cochrane对照试验中心注册库(2016年第8期)、MEDLINE、Embase和CINAHL直至2016年8月9日的随机对照试验(RCT)和准随机试验,纳入需要PSA的急诊科患者,无语言限制。我们检索了元注册库(www.controlled-trials.com、www.clinicalstudyresults.org和clinicaltrials.gov)以查找正在进行的试验(2016年2月)。我们联系了纳入研究的主要作者以及二氧化碳描记法设备制造商的科学顾问以识别未发表的研究(2016年2月)。我们手工检索了2010年至2015年四个组织的会议摘要。
我们纳入了任何比较二氧化碳描记法和标准监测与单纯标准监测用于需要PSA的急诊科患者的RCT或准随机试验。
两位作者独立进行研究选择、数据提取以及为“偏倚风险表”评估方法学质量。对于我们作者参与的任何纳入研究,由一名独立研究人员提取数据。适当时,我们联系纳入研究的作者获取不完整数据。我们使用Review Manager 5合并数据,并使用随机效应模型和固定效应模型计算风险比(RR)和95%置信区间(CI)。
我们确定了三项试验(κ = 1.00),涉及1272名参与者。将二氧化碳描记法组与标准监测组进行比较,氧饱和度降低率(RR 0.89,95% CI 0.48至1.63;n = 1272,3项试验;中等质量证据)和低血压发生率(RR 2.36,95% CI 0.98至5.69;n = 986,1项试验;中等质量证据)无差异。仅记录到1次呕吐事件,两组间无显著差异(RR 3.10,95% CI 0.13至75.88,n = 986,1项试验;中等质量证据)。主要结局的证据质量为中等,主要因异质性和报告偏倚而降级。进行气道干预的发生率无差异(RR 1.26,95% CI 0.94至1.69;n = 1272,3项试验;中等质量证据)。在亚组分析中,我们发现二氧化碳描记法组中成人气道干预发生率较高(RR 1.44,95% CI 1.16至1.79;n = 1118,2项试验;中等质量证据),额外出现有害结局的需治疗人数为12。尽管统计异质性有所降低,但由于结局定义异质性和有限的报告偏倚,证据质量为中等。没有研究报告恢复时间。
缺乏令人信服的证据表明在急诊科PSA中,在标准监测基础上增加二氧化碳描记法能降低具有临床意义的不良事件发生率。由于人群和结局定义的异质性以及有限的报告偏倚,证据被认为质量中等。我们的综述受限于该环境下临床试验数量较少。